Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

Academic Article

• Overview
• Research
• Identity
• Additional Document Info
• View All

Overview

authors

• Papp, K.
• Leonardi, C.
• Menter, A.
• Thompson, Elizabeth
• Milmont, C. E.
• Kricorian, G.
• Nirula, A.
• Klekotka, P.

publication date

• December 2014

journal

• Journal of the American Academy of Dermatology  Journal

subject areas

• Adult
• Antibodies, Monoclonal
• Controlled Clinical Trials as Topic
• Dermatologic Agents
• Dose-Response Relationship, Drug
• Female
• Humans
• Male
• Middle Aged
• Psoriasis
• Receptors, Interleukin-17
• Severity of Illness Index
• Treatment Outcome

Research

keywords

• anti-interleukin-17 therapy
• brodalumab
• clinical trial
• efficacy
• long-term treatment
• open-label extension
• psoriasis
• safety

Identity

International Standard Serial Number (ISSN)

• 0190-9622

Digital Object Identifier (DOI)

• 10.1016/j.jaad.2014.08.039

PubMed ID

• 25313095

Additional Document Info

start page

• 1183

end page

• 1190

volume

• 71

issue

• 6